PFIZER INC Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax
PFIZER INC (PFE) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax of -$44.00 million for the 3-month period ending 2018-04-01, per its 10-Q filed 2018-05-10.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax · last filed 2018-05-10
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2018-04-01 was -$44.00M, a 118.26% decline year-over-year.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2017-12-31 was $127.00M.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2017-10-01 was -$56.00M.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2017-07-02 was $208.00M.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2017 was $520.00M.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2016 was -$452.00M, a 222.83% decline from fiscal 2015.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2015 was $368.00M.
- PFIZER INC other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2014 was -$477.00M, a 607.45% decline from fiscal 2013.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 3 month as first filed | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 6 month as first filed | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 9 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 9 month as first filed | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2018-04-01 | -$44.00M 10-Q · filed 2018-05-10 | $83.00M derived: sum of 2 quarters · filed 2018-05-10 | $27.00M derived: sum of 3 quarters · filed 2018-05-10 | $235.00M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-12-31 | $127.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $71.00M derived: sum of 2 quarters · filed 2018-02-22 | $279.00M derived: sum of 3 quarters · filed 2018-02-22 | $520.00M 10-K · filed 2018-02-22 | |||
| 2017-10-01 | -$56.00M 10-Q · filed 2017-11-09 | $152.00M derived: sum of 2 quarters · filed 2017-11-09 | $393.00M 10-Q · filed 2017-11-09 | $221.00M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-07-02 | $208.00M 10-Q · filed 2017-08-10 | $449.00M 10-Q · filed 2017-08-10 | $277.00M derived: sum of 3 quarters · filed 2018-05-10 | $127.00M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-04-02 | $241.00M 10-Q · filed 2018-05-10 | $69.00M derived: sum of 2 quarters · filed 2018-05-10 | -$81.00M derived: sum of 3 quarters · filed 2018-05-10 | -$550.00M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2016-12-31 | -$172.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$322.00M derived: sum of 2 quarters · filed 2018-02-22 | -$791.00M derived: sum of 3 quarters · filed 2018-02-22 | -$452.00M 10-K · filed 2018-02-22 | |||
| 2016-10-02 | -$150.00M 10-Q · filed 2017-11-09 | -$619.00M derived: sum of 2 quarters · filed 2017-11-09 | -$280.00M 10-Q · filed 2017-11-09 | -$457.00M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2016-07-03 | -$469.00M 10-Q · filed 2017-08-10 | -$130.00M 10-Q · filed 2017-08-10 | -$307.00M derived: sum of 3 quarters · filed 2018-02-22 | -$272.00M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2016-04-03 | $339.00M 10-Q · filed 2017-05-11 | $162.00M derived: sum of 2 quarters · filed 2018-02-22 | $197.00M derived: sum of 3 quarters · filed 2018-02-22 | $940.00M derived: sum of 4 quarters · filed 2018-02-22 | |||
| 2015-12-31 | -$177.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$142.00M derived: sum of 2 quarters · filed 2018-02-22 | $601.00M derived: sum of 3 quarters · filed 2018-02-22 | $368.00M 10-K · filed 2018-02-22 | |||
| 2015-09-27 | $35.00M 10-Q · filed 2016-11-10 | $778.00M derived: sum of 2 quarters · filed 2016-11-10 | $545.00M 10-Q · filed 2016-11-10 | $594.00M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-06-28 | $743.00M 10-Q · filed 2016-08-11 | $510.00M 10-Q · filed 2016-08-11 | $559.00M derived: sum of 3 quarters · filed 2017-02-23 | $118.00M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-03-29 | -$234.00M 10-Q · filed 2016-05-12 | -$184.00M derived: sum of 2 quarters · filed 2017-02-23 | -$625.00M derived: sum of 3 quarters · filed 2017-02-23 | -$699.00M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2014-12-31 | $50.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$391.00M derived: sum of 2 quarters · filed 2017-02-23 | -$465.00M derived: sum of 3 quarters · filed 2017-02-23 | -$477.00M 10-K · filed 2017-02-23 | |||
| 2014-09-28 | -$441.00M 10-Q · filed 2015-11-05 | -$515.00M derived: sum of 2 quarters · filed 2015-11-05 | -$527.00M 10-Q · filed 2015-11-05 | -$470.00M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-29 | -$74.00M 10-Q · filed 2015-08-06 | -$86.00M 10-Q · filed 2015-08-06 | -$29.00M derived: sum of 3 quarters · filed 2016-02-29 | $310.00M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-30 | -$12.00M 10-Q · filed 2015-05-07 | $45.00M derived: sum of 2 quarters · filed 2016-02-29 | $384.00M derived: sum of 3 quarters · filed 2016-02-29 | $608.00M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $57.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $396.00M derived: sum of 2 quarters · filed 2016-02-29 | $620.00M derived: sum of 3 quarters · filed 2016-02-29 | $94.00M 10-K · filed 2016-02-29 | |||
| 2013-09-29 | $339.00M 10-Q · filed 2014-11-06 | $313.00M 10-Q · filed 2013-11-08 | $563.00M derived: sum of 2 quarters · filed 2014-11-06 | $37.00M 10-Q · filed 2014-11-06 | $64.00M 10-Q · filed 2013-11-08 | $559.00M derived: sum of 4 quarters · filed 2015-02-27 | |
| 2013-06-30 | $224.00M 10-Q · filed 2014-08-07 | $132.00M 10-Q · filed 2013-08-09 | -$302.00M 10-Q · filed 2014-08-07 | -$249.00M 10-Q · filed 2013-08-09 | $220.00M derived: sum of 3 quarters · filed 2015-02-27 | $441.00M derived: sum of 4 quarters · filed 2015-02-27 | |
| 2013-03-31 | -$526.00M 10-Q · filed 2014-05-08 | -$4.00M derived: sum of 2 quarters · filed 2015-02-27 | $217.00M derived: sum of 3 quarters · filed 2015-02-27 | -$210.00M derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2012-12-31 | $522.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $743.00M derived: sum of 2 quarters · filed 2015-02-27 | $316.00M derived: sum of 3 quarters · filed 2015-02-27 | $616.00M 10-K · filed 2015-02-27 | |||
| 2012-09-30 | $221.00M 10-Q · filed 2013-11-08 | -$206.00M derived: sum of 2 quarters · filed 2013-11-08 | $94.00M 10-Q · filed 2013-11-08 | ||||
| 2012-07-01 | -$427.00M 10-Q · filed 2013-08-09 | -$127.00M 10-Q · filed 2013-08-09 | |||||
| 2011-12-31 | -$537.00M 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |